Amgen Inc.

AMGN

US0311621009

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 13/02/2026 GMT			5-day change	1st Jan Change
369.19 ^USD	+1.52%		-3.94%	+12.80%

02-12	Amgen Inc. Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium, Feb-12-2026 05:00 PM
02-12	European Commission approves Amgen's Uplizna® for generalized myasthenia gravis	RE

Amgen: Second year of Maritide treatment very well tolerated including at quarterly doses, with very low incidence of nausea, vomiting & no new safety signals observed

Published on 01/12/2026 at 11:54 pm GMT

Reuters

Latest news about Amgen Inc.

02-12	Amgen Inc. Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium, Feb-12-2026 05:00 PM
02-12	European Commission approves Amgen's Uplizna® for generalized myasthenia gravis	RE
02-12	European Commission Approves Amgen's UPLIZNA for Generalized Myasthenia Gravis	CI
02-10	Mizuho Raises Price Target on Amgen to $295 From $280, Keeps Outperform Rating	MT
02-10	Daiwa Securities Adjusts Price Target on Amgen to $410 From $370, Maintains Outperform Rating	MT
02-06	Guggenheim Adjusts Price Target on Amgen to $347 From $305, Maintains Neutral Rating	MT
02-06	Argus Research Adjusts Price Target on Amgen to $400 From $360, Maintains Buy Rating	MT
02-05	CVS Health to drop Amgen and Lilly's bone disease treatments from some drug lists (February 5)	RE
02-05	Deutsche Bank Adjusts Amgen Price Target to $295 From $285, Maintains Hold Rating	MT
02-04	Health Care Up After Eli Lilly Earnings -- Health Care Roundup	DJ
02-04	Sector Update: Health Care Stocks Rise Late Afternoon	MT
02-04	Amgen Seen Driving Long-Term Growth on R&D Pipeline, Oppenheimer Says	MT
02-04	Novo Nordisk exposed to a price war over obesity treatments
02-04	Novo Nordisk risks weight-loss price war as discount pressures deepen	RE
02-04	TD Cowen Adjusts Price Target on Amgen to $420 From $389, Maintains Buy Rating	MT

Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (95.8%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other 4.2%): primarily royalties. The United States account for 71.4% of net sales.

Employees

28,000

Sector

Pharmaceuticals

Calendar

04-28 - Q1 2026 Earnings Release (Projected)

More about the company